Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer (Q37815444)

23 August 2017

Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer (English)

1 reference

23 August 2017

3

Narikazu Boku

1 reference

23 August 2017

Takahiro Tsushima

1

1 reference

23 August 2017

Shuichi Hironaka

2

1 reference

23 August 2017

Nozomu Machida

4

1 reference

23 August 2017

Kentaro Yamazaki

5

1 reference

23 August 2017

Hirofumi Yasui

6

1 reference

23 August 2017

Keisei Taku

7

1 reference

23 August 2017

Akira Fukutomi

8

1 reference

23 August 2017

Yusuke Onozawa

9

1 reference

23 August 2017

1 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

13

1 reference

23 August 2017

4

1 reference

23 August 2017

245-250

1 reference

https://scigraph.springernature.com/pub.10.1007/s10120-010-0566-z

23 August 2017

0 references

cites work

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10120-010-0566-Z

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10120-010-0566-Z

Longitudinal studies on the rate of decline in renal function with age.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10120-010-0566-Z

Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts

21 January 2018

1 reference

12 December 2020

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

12 December 2020

Epidemiology of gastric cancer in Japan

1 reference

12 December 2020

Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study

1 reference

12 December 2020

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

12 December 2020

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

12 December 2020

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

12 December 2020

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

12 December 2020

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

1 reference

12 December 2020

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

12 December 2020

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

1 reference

12 December 2020

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

12 December 2020

International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.

1 reference

12 December 2020

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

12 December 2020

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

1 reference

12 December 2020

Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy

1 reference

12 December 2020

Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer

1 reference

12 December 2020

A case for geriatric oncology

1 reference

12 December 2020

Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research

1 reference

12 December 2020

Clinical pharmacology of cancer therapies in older adults.

1 reference

12 December 2020

Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

1 reference

12 December 2020

Epidemiology of gastric cancer and perspectives for prevention.

1 reference

12 December 2020

Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group

1 reference

12 December 2020

Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug

1 reference

12 December 2020

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

1 reference

12 December 2020

10.1007/S10120-010-0566-Z

Identifiers

DOI

1 reference

23 August 2017

1 reference